Laboratory News and Emerging Issues
2021-2022 Influenza Surveillance
Appropriate treatment of patients with respiratory illness depends on accurate and timely diagnosis. Early diagnosis of influenza can reduce the inappropriate use of antibiotics and provide the option of using antiviral therapy.
Surveillance for the 2021-2022 influenza season officially begins on October 9, 2020. Receiving the first positive influenza specimens in the state is important in determining the circulating strains and prevalence. The Montana Public Health Laboratory (MTPHL) also shares these specimens with the Centers for Disease Control for further characterization and antiviral resistance testing.
Due to the Covid-19 pandemic, we may have limited capacity and may not be able to perform all influenza testing in-house on a daily basis. MTPHL will remain focused on Covid testing and influenza surveillance, as long as resources are available.
- 2021-2022 surveillance testing guidelines
- 2021-2022 diagnostic testing guidelines
- 2021-2022 surveillance sites
For information about influenza activity in the United States during the influenza season, visit the Weekly U.S. Influenza Surveillance Report (FluView)
Information regarding the 2019 Novel Coronavirus is evolving. At this point, we are trying to prioritize patients at high risk. Please document on the MTPHL request form the patient status and work with local or state epidemiology staff (406-444-0273) concerning priority patients. Please see the MTPHL guidance document for more information, and if you are not receiving communications about COVID-19 from MTPHL, contact Crystal Fortune, email@example.com to be added to our email database. Contact the Montana Public Health Laboratory if you have questions not covered in our guidance document below: (800) 821-7284 or (406) 444-3444.
Additional guidance is available on CDC's website:
- Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Patients Under Investigation for 2019 Novel Coronavirus
- Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with 2019 Novel Coronavirus
Change in Reportable Conditions
Add-On Request for Mycobacteriology
We recently updated the “Add-on Test” request form for use when requesting additional testing on Mycobacteria spp. isolates. This updated version provides a little more clarity on the testing choices, including susceptibility testing for Mycobacterium avium complex (MAC) isolates. Please view and/or print the updated Add-on Test form and let us know if you have any questions. 800-821-7284
Zika Testing Guidance
Based on the current global epidemiology of dengue and Zika viruses, CDC recommends that state, territorial and local health departments and laboratories review and update their Zika virus testing practices. Routine serological testing for Zika virus is no longer recommended; further details are provided in the CDC's November 14, 2019 letter on Zika testing.
Aptima Multitest Swab Collection
We are encouraging lesion swabs for Herpes testing to be collected using the new Aptima Multitest Swab Specimen Collection Kits. Please distribute the information, found in the August 30, 2019 MT Laboratory Sentinel Newsletter, to your providers as needed. Copy of the product insert from Hologic.
On June 1, 2019, the Montana Public Health Laboratory (MTPHL) is implementing a process that will re-quire clinical laboratories to include a daily specimen manifest with all submissions. The use of daily manifests will allow us to better track all specimens from the time they leave your location to receipt at MTPHL. Each manifest will be reconciled with the actual specimens received and if any discrepancy is noted, you will be alerted immediately. All manifest will be kept for a minimum of 30 days.
If you are not currently able to produce your own patient manifest for submission of specimens to MTPHL, please click the following link for a generic manifest template. Frequently asked questions can be found by clicking on the following link: Specimen Transport Bag and Manifest FAQ
Candida auris Information
The Montana Public Health Laboratory, in conjunction with CDC’s Antimicrobial Resistance Laboratory Network (ARLN), is set to detect resistant organisms that pose a public health threat and interested in receiving these isolates for further surveillance testing. This request includes all Candida species other than C. albicans from any source, especially invasive sites.
Norovirus season is upon us and the Montana Department of Health and Human Services (DPHHS) needs your help this season to improve our outbreak surveillance regarding Norovirus in Montana. Gastroenteritis outbreaks or any outbreaks that occur in congregate settings such as schools, nursing homes and child cares are reportable and provide a glimpse inside infectious diseases in Montana. DPHHS is asking our partners to do their part to improve our understanding of norovirus in Montana.
Wanted!! Carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa (CRPA) isolates
To submit a question or comment to Laboratory Services, please click on the suggestion box to access our online form.